Pharmacokinetic profile of levetiracetam: toward ideal characteristics (Q33866334)

29 July 2017

1 reference

title

Pharmacokinetic profile of levetiracetam: toward ideal characteristics (English)

1 reference

29 July 2017

1 reference

1 reference

Patsalos PN

1 reference

29 July 2017

publication date

1 February 2000

1 reference

Pharmacology & Therapeutics

29 July 2017

published in

1 reference

29 July 2017

1 reference

29 July 2017

1 reference

29 July 2017

page(s)

77-85

1 reference

Pharmacokinetics of antiepileptic drugs

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900052-2

7 January 2021

Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900052-2

7 January 2021

Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900052-2

7 January 2021

Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900052-2

7 January 2021

Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900052-2

7 January 2021

The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900052-2

7 January 2021

Phenobarbitone to gabapentin: a guide to 82 years of anti-epileptic drug pharmacokinetic interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900052-2

7 January 2021

The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900052-2

7 January 2021

A micromethod for the determination of the new antiepileptic drug levetiracetam (ucb LO59) in serum or plasma by high performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900052-2

7 January 2021

Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900052-2

7 January 2021

Some aspects of prognosis in the epilepsies: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900052-2

7 January 2021

Efficacy and tolerability study of ucb L059 in patients with refractory epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900052-2

7 January 2021

Neurochemical studies with the novel anticonvulsant levetiracetam in mouse brain

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900052-2

7 January 2021

Antiepileptogenic effects of conventional anticonvulsants in the kindling model of epilespy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900052-2

7 January 2021

Clinical pharmacokinetics of new antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2899%2900052-2

7 January 2021

10.1016/S0163-7258(99)00052-2

Identifiers

DOI

1 reference

29 July 2017

1 reference